Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060114 | 0.93 | CPB1 (0.53) | CPB1CPB2PSMB5PTGER4FOLH1 | |
| SCHEMBL31060112 | 0.93 | CPB1 (0.52) | CPB1CPB2PSMB5PTGER4FOLH1 | |
| SCHEMBL29942304 | 0.90 | CPB1 (0.47) | CPB1CPB2PSMB5PTGER4FOLH1 | |
| SCHEMBL29831802 | 0.90 | CPB1 (0.46) | CPB1CPB2PSMB5PTGER4FOLH1 | |
| SCHEMBL30804252 | 0.89 | KLK7 (0.51) | CPB1CPB2PSMB5 | |
| SCHEMBL29832684 | 0.88 | KLK7 (0.52) | CPB1CPB2PSMB5 | |
| SCHEMBL29832028 | 0.86 | CPB1 (0.45) | CPB1CPB2PSMB5PTGER4FOLH1 | |
| SCHEMBL29942383 | 0.86 | KLK7 (0.49) | CPB1CPB2PSMB5PTGER4FOLH1 | |
| SCHEMBL29942669 | 0.86 | CPB1 (0.53) | CPB1CPB2PSMB5PTGER4FOLH1 | |
| SCHEMBL29832284 | 0.85 | CPB1 (0.44) | CPB1CPB2PSMB5PTGER4FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213645-A1 | PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE | L-Base Co., Ltd. (KR) | 2025-07-03 | — | — | US | disclosed |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-06-27 | — | — | US | disclosed |
| EP-4062974-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L BASE CO LTD (KR) | 2024-05-08 | — | — | EP | disclosed |
| EP-4335452-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-03-13 | — | — | EP | disclosed |
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L-Base Co., Ltd. (KR) | 2023-05-25 | — | — | US | disclosed |
| WO-2023043261-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | 주식회사 엘베이스 | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043271-A1 | METHOD FOR CHARACTERIZING RESPONDER TO CAGE INHIBITOR FOR CANCER THERAPY | 주식회사 엘베이스 | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043269-A1 | PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE | 주식회사 엘베이스 | 2023-03-23 | — | — | WO | disclosed |
| WO-2022203219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER | 주식회사 엘베이스 | 2022-09-29 | — | — | WO | disclosed |
| EP-4062974-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L-Base Co.,Ltd. (KR) | 2022-09-28 | — | — | EP | disclosed |
| WO-2022197100-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | 주식회사 엘베이스 | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | VIP, QPCT, TPT1 | CPB1 894/4885CPB2 1448/4885PSMB5 1445/4885 |
| US-20250213645-A1 | PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE | ATG7, CCL11, ATG13 | CPB1 627/4885CPB2 1499/4885PSMB5 1891/4885 |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | ALPG, SLC11A2, SGTA | CPB1 2332/4885CPB2 3366/4885PSMB5 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.